RecruitingNCT04814407
Developing Novel Circulating Epigenetic Biomarkers for Early Detection of Lung Cancer
Sponsor
National Taiwan University Hospital
Enrollment
900 participants
Start Date
Mar 1, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
The investigators aim to identify novel circulating methylated biomarkers for early lung cancer detection as well as to develop new technologies that are clinically applicable with high sensitivity and specificity.
Eligibility
Min Age: 20 Years
Inclusion Criteria4
- Subjects suspected or confirmed diagnosis of lung cancer.
- Subjects who had indeterminate sub-centimeter pulmonary nodules or ground glass opacities discovered by computed tomography.
- Non-cancer subjects: including healthy volunteers and chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc.
- Subjects age over 20.
Exclusion Criteria3
- Pregnancy.
- Subjects with HIV infection.
- Unable to or unwilling to give informed consent.
Interventions
DIAGNOSTIC_TESTBlood-derived DNA methylation detection
Up to 20 ml of blood will be collected from each subject, and the blood specimen will be processed to isolate plasma cell-free DNA and immune-derived cells (circulating T cells). Circulating methylated tumor/immune signature will then be identified.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04814407
Related Trials
Virtual Agent Feasibility in Oncology Patients (NTT Data)
NCT066820131 location
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
Lung Cancer Screening in HIgh Risk nonsmokErs by Artificial inteLligence Device
NCT062954971 location
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Mid-transverse Process Combined With Erector Spinae Block Versus Paravertebral Plane Block
NCT066185991 location